Monitoring of subcutaneous dalteparin in patients with renal insufficiency under intensive care: an observational study

Journal of Critical Care

Volumn 21, Issue 1, 2006, Pages 79-84

  Kani, Chara ^a   Markantonis, Sophia L ^a   Nicolaou, Chara ^b   Maggina, Nina ^b  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b Intensive Care Unit   (Greece)

Author keywords

Dalteparin; Intensive Care Unit; Pharmacokinetics

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; CREATININE; DALTEPARIN; DOBUTAMINE; DOPAMINE; INOTROPIC AGENT; NORADRENALIN;

ADULT; AGED; ANAPHYLAXIS; ANTICOAGULATION; ARTICLE; ASSAY; BLEEDING; BLOOD CLOTTING; CLINICAL ARTICLE; CLINICAL TRIAL; CORRELATION ANALYSIS; CREATININE CLEARANCE; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG FEVER; EDEMA; ERYTHEMA; FEMALE; HEMATOMA; HUMAN; INJECTION SITE REACTION; INTENSIVE CARE; INTENSIVE CARE UNIT; KIDNEY FAILURE; KIDNEY FUNCTION; MACULOPAPULAR RASH; MALE; OBSERVATIONAL STUDY; PATIENT MONITORING; SKIN NECROSIS; THROMBOCYTOPENIA; THROMBOSIS;

AGED; ANTICOAGULANTS; CRITICAL ILLNESS; DALTEPARIN; FEMALE; HUMANS; INTENSIVE CARE; MALE; OBSERVATION; PROSPECTIVE STUDIES; RENAL INSUFFICIENCY; STATISTICS, NONPARAMETRIC;

EID: 33646006735     PISSN: 08839441     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jcrc.2005.09.056     Document Type: Article

References (14)

1. Hirsh J., Warkentin T.E., Raschke R., et al. Heparin and low-molecular-weight heparin. Mechanisms of action, pharmacokinetics, dosing, considerations, monitoring, efficacy, and safety. Chest 114 (1998) 489S-510S
2. Berry B.R., and Nantel S. Heparin therapy-current regimens and principles of monitoring. Postgrad Med 6 (1996) 64S-76S
3. Borm J.J., Krediet R., and Sturk A. Heparin versus low molecular weight heparin K 2165 in chronic hemodialysis patients: a randomized cross-over study. Haemostasis 16 Suppl 2 (1986) 59-68
4. Collignon F., Frydman A., Caplain H., et al. Comparison of the pharmacokinetic profiles of three low molecular mass heparins-dalteparin, enoxaparin and nadroparin-administered subcutaneously in healthy volunteers (doses for prevention of thromboembolism). Thromb Haemost 73 (1995) 630-640
5. Goudable C., Saivin S., Houin G., et al. Pharmacokinetics of low molecular weight heparin (Fraxiparine) in various stages of chronic renal insufficiency. Nephron 59 (1991) 543-545
6. Cadroy Y., Pourrat J., Baladre M.F., et al. Delayed elimination of enoxaparin in patients with chronic renal insufficiency. Thromb Res 63 (1991) 385-390
7. Palm M., and Mattsson C. Pharmacokinetics of fragmin. A comparative study in the rabbit of its high and low affinity forms for antithrombin. Thromb Res 48 (1987) 51-62
8. Spiegel D.M., and Anderson R.J. Is low-molecular-weight heparin useful for venovenous hemofiltration in the intensive care unit?. Crit Care Med 27 (1999) 2316S-2317S
9. Howard P. Low molecular weight heparins in special populations. J Infus Nurs 26 (2003) 304-310
10. STA Rotachrome HBPM/LMWH-colorimetric assay of LMWH by STA analysers. Diagnostica Stago, Asnieres-Sur-Seine, France.
11. Makris A., and Pithara E.L. Clinical evaluation of new global clotting assay for monitoring of LMWH treatment: pilot study. Int Angiol 17 (1998) 69-79
12. Sanderink G.J., Guimart C.G., Ozoux M.L., et al. Pharmacokinetics and pharmacodynamics of the prophylactic dose of enoxaparin once daily over 4 days in patients with renal impairment. Thromb Res 105 (2002) 225-231
13. Fragmin product monograph (Pharmacia-Canada). Rev 11/94, Rec 4/95; Rev 4/97, Rec 6/97.
14. Dorffler Melly J., de Jonge E., Pont A.C., et al. Bioavailability of subcutaneous low-molecular-weight heparin to patients on vasopressors. Lancet 359 (2002) 849-850